Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ, CrystalGenomics Enter Antibiotic Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AZ, CrystalGenomics Enter Antibiotic Pact

AstraZeneca and Korea-based CrystalGenomics have entered into a research collaboration to discover and develop a novel anti-infective for use as a potential antibacterial agent.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca and Korea-based CrystalGenomics have entered into a research collaboration to discover and develop a novel anti-infective for use as a potential antibacterial agent. CrystalGenomics will receive research funding from AZ for two years and will be eligible to receive future milestones and royalty payments associated with development and commercialization of a drug candidate. Financial terms were not disclosed.

CrystalGenomics will use its structure-based drug discovery platform technology to optimize selected novel scaffolds from AZ’s compound library against an antibacterial target, which has been validated by AZ. Both companies will perform in-vitro enzyme and cell based assays, structure determination, medicinal chemistry, pharmacokinetic studies, toxicology tests and pharmacological evaluations. AZ will be responsible for preclinical and clinical development and commercialization.

Les Hughes, AstraZeneca’s vice president of Infection Discovery, said, “AstraZeneca is building a leading franchise in the treatment of infectious diseases, both through our own in-house research as well as collaborations such as this partnership with CrystalGenomics. Infectious disease remains a serious world health problem and AstraZeneca is committed to finding therapies that will tackle a wide range of serious infections afflicting mankind.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics